Drug delivery methods are changing in many ways to inhalants if possible. Why, because they can be used with devices that report data to enforce compliance, 
perhaps easier than swallowing a chip and watching its “Fantastic Voyage”. If you don’t get that last remark you are too young to remember. These folks that I correspond with in the UK and in Massachusetts at Cambridge have some pretty exotic devices too and they state that drug delivery lies with new technology. They have their own blue tooth inhaler out there.
The Future of Drug Delivery Lies with Technology – Panel of Experts From Cambridge Consultants
On the OptiNose page you can see where there is an inquiry section for pharma or biotech companies to get in touch to evaluate the nasal delivery system. Also, guess what, the inhalers take either powder or liquid and are either in multi or single use devices. I hope it is sealed to avoid inhaling other drugs that perhaps are not legal out there. This is one more example where inhaled drugs are making their way into treatment plans today. Sinusitis can also be treated with the inhaler. BD
Oslo, April 7, 2010: OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.
Sumatriptan powder in 10mg and 20mg doses administered intranasally using OptiNose’s bi-directional delivery device was highly effective in treating a single attack of moderate or severe migraine. The proportion of patients pain-free at two hours was 54% for the 10 mg dose, 57% for 20 mg and 25% for placebo (P< .05). These results compare very favorably with published figures of 26-42% for liquid sumatriptan nasal spray and 35.6% for zolmitriptan nasal spray and higher than the 28% /29% reported for oral triptans. In addition to high efficacy, OptiNose’s bi-directional powder delivery eliminates drip-out and reduces the bitter taste associated with conventional nasal triptan products.
About OptiNose Bi-directional Delivery Devices:
OptiNose’s unique breath actuated devices deliver intranasal drugs to targeted regions in the nasal cavity, including the sinus openings and the olfactory region. This is achieved without any risk of lung deposition, unlike traditional nasal inhalers, nasal sprays or nebulizers. The Company offers both single and multi-use intranasal delivery devices for liquid and powder formulations. Core patents have been granted in Europe and the US. Variants of the basic delivery system are available for powder and liquid delivery. The technology has been successfully tested in a number of clinical trials to date including gamma scintigraphy studies to confirm highly superior deposition, studies evaluating the immune response to conventional antigens, trials showing excellent effects in chronic sinusitis with and without nasl polyps and studies evaluating the delivery of CNS active compounds. The results have confirmed the superiority of the technology compared to traditional nasal sprays.
We can deliver our drugs straight to your door, try our service
ReplyDelete